Pregled bibliografske jedinice broj: 402621
Immunomodulation with interleukin-2 impruves antitumor effect of chemotherapy and thermotherapy
Immunomodulation with interleukin-2 impruves antitumor effect of chemotherapy and thermotherapy // Annual Meeting of the Croatian Immunological Society
Šibenik, Hrvatska, 2008. str. 61-61 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 402621 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Immunomodulation with interleukin-2 impruves antitumor effect of chemotherapy and thermotherapy
Autori
Oršolić, Nada ; Bevanda, Milenko ; Bašić, Ivan ; Kujundžić, Milan ;
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Annual Meeting of the Croatian Immunological Society
/ - , 2008, 61-61
Skup
Annual Meeting of the Croatian Immunological Society
Mjesto i datum
Šibenik, Hrvatska, 09.10.2008. - 12.10.2008
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
Carcinomatosis; Interleukin-2; tumor; chemotherapy; thermotherapy
Sažetak
Peritoneal carcinomatosis is prognostically a very bad sign and common cause of death in patients with gastrointestinal and gynecologic tumors. The aim of this study was to explore and compare different models of locoregional immunochemotherapy, hyperthermial intraperitonal chemotherapy (HIPEC) in animal model of induced peritoneal carcinomatosis in mice. Material and methods: CBA mice were injected with mammary carcinoma (MCa) cells intraperitoneally (ip) inducting peritoneal carcinomatosis. In preventional model biological response modifiers (BRM), interleukin-2 (IL-2) at dose of 4.1 x 104 IU/mouse was injected into abdominal cavity seven and three days before injection of tumor cells, respectively. Immediately after the injection of tumor cells, heated saline at 37°C or at 43°C was injected ip (hyperthermia treatment). Following this mice were ip treated with doxorubicin (DOX) 20 mg kg-1, cisplatin (CIS) 10 mg kg-1, mitomicyn (MIT) 5 mg kg-1, 5- fluorouracil (5-FU) 150 mg kg-1 either separately or in combination of them. In therapeutic model cytostatics were injected on day 5 after injection of tumor cells. Hyperthermia treatment was performed immediately before injection of cytostatic drugs. Results: Results showed significant difference in surviving time (engl. increased life span ; ILS%) of mice pretreated with IL-2 and treated with hyperthermic chemotherapy compared with control: IL-2+ CIS (ILS%=260, 50) ; IL-2+ DOX + CIS (ILS%=200) ; IL-2 + MIT (ILS%=178, 05) ; IL-2 + CDL (ILS%=70, 20) ; IL-2+ DOX (ILS%=67, 92) ; IL-2 + 5-FU (ILS%=62, 69) ; IL-2+ 5-FU+ DOX (ILS%=55, 22). Treatment with IL-2+ 5-FU+ CIS was shown to be toxic to mice since all mice died before control group. Conclusion: The results suggest the synergistic effect of hyperthermia, chemotherapy and immunotherapy ; IL-2 significantly increases antitumor activity of hyperthermic chemotherapy and survival rate of mice with peritoneal carcinomatosis. It is likely that stimulative effect of IL
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-3114 - HELICOBAKTER PYLORI INFEKCIJA - EVOLUCIJA BOLESTI I NOVI TERAPIJSKI POSTUPCI (Katičić, Miroslava, MZOS ) ( CroRIS)
119-0000000-1255 - Kemoprevencija rasta tumora polifenolnim sastavnicama (Oršolić, Nada, MZOS ) ( CroRIS)
119-0532265-1254 - Imunoadjuvantno i zaštitno djelovanje propolisa u životinja (Benković, Vesna, MZOS ) ( CroRIS)
198-0000000-1124 - Bolesti pankreato-bilijarnog sustava: etiologija, dijagnostika i terapija (Kujundžić, Milan, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb,
Klinička bolnica "Dubrava"